AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31871140 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-α kinoid (IFN-K)
Number of subjects: 185
Study 31871140 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 185
Study 31069442 — intervention group
Group type: EXPERIMENTAL
Intervention: Low baseline 25OHD < 25 nmol/L
Number of subjects: 975
Study 31069442 — intervention group
Group type: COMPARATOR
Intervention: Baseline 25OHD ≥ 50 nmol/L
Number of subjects: 975
Study 28325612 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin T (hs‐TnT)
Number of subjects: 1937
Study 28325612 — intervention group
Group type: COMPARATOR
Intervention: Conventional troponin T (c‐TnT)
Number of subjects: 1937
Study 24158313 — intervention group
Group type: EXPERIMENTAL
Intervention: Early removal group (chest tube removal at drainage volume of 300 ml/24 h or less)
Number of subjects: 70
Study 24158313 — intervention group
Group type: COMPARATOR
Intervention: Traditional management group (chest tube removal when drainage volume is less than 100 ml/24 h)
Number of subjects: 70
Study 24158313 — intervention group
Group type: EXPERIMENTAL
Intervention: Early removal group
Number of subjects: 70
Study 24158313 — intervention group
Group type: COMPARATOR
Intervention: Traditional management group
Number of subjects: 70
Study 24158313 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study 24032186 — intervention group
Group type: EXPERIMENTAL
Intervention: Nape acupuncture combined with rehabilitation training
Number of subjects: 80
Study 24032186 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (general medication + rehabilitation training)
Number of subjects: 80
Study 20599816 — intervention group
Group type: EXPERIMENTAL
Intervention: Attend-to-face condition
Number of subjects: 0
Study 20599816 — intervention group
Group type: COMPARATOR
Intervention: Ignore-faces condition with similar faces
Number of subjects: 0
Study 20599816 — intervention group
Group type: COMPARATOR
Intervention: Ignore-faces condition with dissimilar faces
Number of subjects: 0
Study 20599816 — intervention group
Group type: EXPERIMENTAL
Intervention: Attend-to-face vs. ignore-faces condition
Number of subjects: 0
Study 18699970 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of a preferred chewing side (PCS)
Number of subjects: 4086
Study 15959612 — intervention group
Group type: EXPERIMENTAL
Intervention: Bethanechol (30 mg/day)
Number of subjects: 79
Study 15959612 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (30 mg/day)
Number of subjects: 79
Study 15959612 — intervention group
Group type: EXPERIMENTAL
Intervention: Bethanechol combined with cisapride (30 mg/day each)
Number of subjects: 79
Study 15959612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 12642049 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2a (10 million units/m2, daily for 7 days)
Number of subjects: 112
Study 12642049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 10757556 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine (1000 mg absolute)
Number of subjects: 31
Study 10757556 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin/ifosfamide-based chemotherapy without amifostine (Control)
Number of subjects: 31
Study 8955958 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoreactivity for NF-kappa B in glial cells of infarcted areas
Number of subjects: 0
Study 8955958 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoreactivity for NF-kappa B in macrophages
Number of subjects: 0
Study 8955958 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoreactivity for NF-kappa B in capillaries
Number of subjects: 0
Study 1383970 — intervention group
Group type: EXPERIMENTAL
Intervention: HIGH stimulation group
Number of subjects: 37
Study 1383970 — intervention group
Group type: COMPARATOR
Intervention: LOW stimulation group
Number of subjects: 37
Study 3904977 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific Immunotherapy Group - three monthly doses of 500 micrograms of tumor associated antigen (TAA) emulsified with complete Freund's adjuvant (CFA)
Number of subjects: 86
Study 3904977 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonspecific Immunotherapy Group - three monthly doses of CFA emulsified in saline
Number of subjects: 86
Study 3904977 — intervention group
Group type: COMPARATOR
Intervention: Control Group - no treatment postoperatively
Number of subjects: 86
Study 30639758 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized, interactive intervention tailored to readiness for advanced care planning and prognostic information
Number of subjects: 460
Study 30639758 — intervention group
Group type: COMPARATOR
Intervention: Symptom-management educational treatment (Control)
Number of subjects: 460
Study 30639758 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized, interactive intervention
Number of subjects: 460
Study 28990437 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection volume of 2250 µL
Number of subjects: 80
Study 28990437 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection site in thigh
Number of subjects: 80
Study 28990437 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection speed (0-800 µL/sec)
Number of subjects: 80
Study 28990437 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient acceptance of injection pain
Number of subjects: 80
Study 26873905 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 3300
Study 25288600 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional Care Model (TCM) intervention delivered by a psychiatric nurse practitioner for 90 days posthospitalization
Number of subjects: 40
Study 25288600 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional Care Model (TCM) intervention
Number of subjects: 40
Study 25288600 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study 22843761 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbonated water
Number of subjects: 39
Study 22843761 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold water (4 °C)
Number of subjects: 39
Study 20056354 — intervention group
Group type: EXPERIMENTAL
Intervention: 68 Gy
Number of subjects: 557
Study 20056354 — intervention group
Group type: EXPERIMENTAL
Intervention: 76-78 Gy
Number of subjects: 557
Study 20056354 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder surface receiving >or=80 Gy
Number of subjects: 557
Study 20056354 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose difference map in bladder neck (trigonal region)
Number of subjects: 557
Study 20056354 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline complaints and transurethral resection of the prostate
Number of subjects: 557
Study 20056354 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute complaints
Number of subjects: 557
Study 17934937 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol/betamethasone dipropionate (Dovobet) for 4 weeks followed by calcipotriol for 8 weeks (group A)
Number of subjects: 150
Study 17934937 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriol (Daivonex) alone for 12 weeks (group B)
Number of subjects: 150
Study 16227729 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic dacryocystorhinostomy with bicanalicular silicone tube implantation
Number of subjects: 24
Study 16227729 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic dacryocystorhinostomy without bicanalicular silicone tube implantation
Number of subjects: 24
Study 16227729 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic dacryocystorhinostomy
Number of subjects: 24
Study 11940375 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEAS (100 mg q.d.) for 6 months
Number of subjects: 86
Study 11940375 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 86
Study 11107582 — intervention group
Group type: EXPERIMENTAL
Intervention: Purulent bacterial meningitis (PBM)
Number of subjects: 38
Study 11107582 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral meningitis (VM)
Number of subjects: 38
Study 11107582 — intervention group
Group type: COMPARATOR
Intervention: Control group (meningeal syndrome)
Number of subjects: 38
Study 8571309 — intervention group
Group type: EXPERIMENTAL
Intervention: DIC treatment
Number of subjects: 395
Study 1748139 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (300 mg i.v.)
Number of subjects: 10
Study 1748139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6760679 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50-150 mg twice daily
Number of subjects: 32
Study 6760679 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol 200-600 mg twice daily
Number of subjects: 32
Study 6760679 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 32
Study 6760679 — intervention group
Group type: COMPARATOR
Intervention: Labetalol
Number of subjects: 32
Study 30923313 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated disease management (IDM)
Number of subjects: 180
Study 30923313 — intervention group
Group type: COMPARATOR
Intervention: Usual physician care
Number of subjects: 180
Study 26786469 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal preventive intervention
Number of subjects: 335
Study 26786469 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained attenders (SA-LI and SA-HI)
Number of subjects: 335
Study 26786469 — intervention group
Group type: EXPERIMENTAL
Intervention: Early dropouts (EDO-LI and EDO-HI)
Number of subjects: 335
Study 26786469 — intervention group
Group type: EXPERIMENTAL
Intervention: EDO-HI group
Number of subjects: 335
Study 26786469 — intervention group
Group type: EXPERIMENTAL
Intervention: SA-LI group
Number of subjects: 335
Study 26675176 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based smoking media literacy (SML) program
Number of subjects: 72
Study 26675176 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 72
Study 24334242 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 120
Study 24334242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 22748976 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.1g of n‐3 PUFA for 6 weeks
Number of subjects: 50
Study 22748976 — intervention group
Group type: COMPARATOR
Intervention: Olive oil for 6 weeks
Number of subjects: 50
Study 20632312 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendicectomy (LA)
Number of subjects: 105
Study 20632312 — intervention group
Group type: COMPARATOR
Intervention: Open appendicectomy (OA)
Number of subjects: 105
Study 17373287 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting
Number of subjects: 0
Study 17373287 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy
Number of subjects: 0
Study 15542566 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocapnic hyperventilation of frigid air (HV)
Number of subjects: 10
Study 15542566 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine (Meth)
Number of subjects: 10
Study 12042891 — intervention group
Group type: EXPERIMENTAL
Intervention: B/HT
Number of subjects: 94
Study 12042891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 10738350 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary angioplasty
Number of subjects: 0
Study 10738350 — intervention group
Group type: COMPARATOR
Intervention: Coronary surgery
Number of subjects: 0
Study 7777693 — intervention group
Group type: EXPERIMENTAL
Intervention: Referential imagery
Number of subjects: 0
Study 7777693 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonreferential imagery
Number of subjects: 0
Study 2407959 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin and Aspirin (active treatment arms)
Number of subjects: 1244
Study 2407959 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 1244
Study 2407959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1244
Study 351808 — intervention group
Group type: EXPERIMENTAL
Intervention: Arecholine (4 milligrams)
Number of subjects: 0
Study 351808 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline (10 grams)
Number of subjects: 0
Study 351808 — intervention group
Group type: COMPARATOR
Intervention: Scopolamine (0.5 milligram)
Number of subjects: 0
Study 351808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31415994 — intervention group
Group type: EXPERIMENTAL
Intervention: Svelte sirolimus‐eluting stent (SES) systems
Number of subjects: 1630
Study 31415994 — intervention group
Group type: COMPARATOR
Intervention: Xience or Promus everolimus‐eluting stents (control)
Number of subjects: 1630
Study 27171136 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400 mg daily)
Number of subjects: 26
Study 27171136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 25588369 — intervention group
Group type: EXPERIMENTAL
Intervention: Moro juice extract (Morosil(®), 400 mg/die)
Number of subjects: 0
Study 25588369 — intervention group
Group type: EXPERIMENTAL
Intervention: Moro juice extract
Number of subjects: 0
Study 24011656 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical cervical manipulation
Number of subjects: 0
Study 24011656 — intervention group
Group type: COMPARATOR
Intervention: Sham-control cervical manipulation
Number of subjects: 0
Study 22106341 — intervention group
Group type: EXPERIMENTAL
Intervention: GH replacement therapy (0.24 mg/day in elderly, 0.33 mg/day in younger)
Number of subjects: 90
Study 22106341 — intervention group
Group type: EXPERIMENTAL
Intervention: GH replacement therapy
Number of subjects: 90
Study 19843623 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (Group I) for 15 days prior to surgery
Number of subjects: 40
Study 19843623 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group II) with no antihyperlipidemic agents
Number of subjects: 40
Study 17602012 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-oriented group intervention with citizenship training and peer support combined with standard clinical treatment
Number of subjects: 114
Study 17602012 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical treatment with jail diversion services alone
Number of subjects: 114
Study 17602012 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (experimental and control)
Number of subjects: 114
Study 15271972 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-implant ball attachment group
Number of subjects: 110
Study 15271972 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-bar group
Number of subjects: 110
Study 15271972 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-bar group
Number of subjects: 110
Study 11476685 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1% plus timolol 0.5%
Number of subjects: 241
Study 11476685 — intervention group
Group type: COMPARATOR
Intervention: Dorzolamide 2% plus timolol 0.5%
Number of subjects: 241
Study 9572104 — intervention group
Group type: EXPERIMENTAL
Intervention: Well-being therapy
Number of subjects: 20
Study 9572104 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral treatment of residual symptoms
Number of subjects: 20
Study 7882817 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide-GITS (controlled-release glipizide)
Number of subjects: 132
Study 7882817 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release glipizide
Number of subjects: 132
Study 7882817 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 132
Study 3147971 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate (MPSS)
Number of subjects: 82
Study 3147971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 31486890 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride plus Olanzapine
Number of subjects: 328
Study 31486890 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine monotherapy (10-20 mg/day)
Number of subjects: 328
Study 31486890 — intervention group
Group type: COMPARATOR
Intervention: Amisulpride monotherapy (400-800 mg/day)
Number of subjects: 328
Study 30027643 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-retroviral treatment (ART)
Number of subjects: 6
Study 27392722 — intervention group
Group type: EXPERIMENTAL
Intervention: TEO First® hearing aid
Number of subjects: 31
Study 24961363 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management (CM) targeting psycho-stimulants
Number of subjects: 126
Study 24961363 — intervention group
Group type: COMPARATOR
Intervention: Non-contingent control condition
Number of subjects: 126
Study 21735527 — intervention group
Group type: EXPERIMENTAL
Intervention: Provisional stenting with drug-eluting stents (DES) in group OR (stenosis < 50% of SB lumen area)
Number of subjects: 60
Study 21735527 — intervention group
Group type: EXPERIMENTAL
Intervention: Provisional stenting with drug-eluting stents (DES) in group SR (stenosis ≥ 50% of SB lumen area)
Number of subjects: 60
Study 21735527 — intervention group
Group type: COMPARATOR
Intervention: Group SR (stenosis ≥ 50% of SB lumen area)
Number of subjects: 60
Study 20375127 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 145
Study 18525392 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard 3-month cardiac rehabilitation program (SCR)
Number of subjects: 392
Study 18525392 — intervention group
Group type: COMPARATOR
Intervention: Distributed cardiac rehabilitation program (DCR)
Number of subjects: 392
Study 15878725 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicated PD patients in a concurrent reading condition of the reproduction task
Number of subjects: 0
Study 15878725 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicated PD patients in a concurrent reading condition of the production task
Number of subjects: 0
Study 15878725 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicated PD patients
Number of subjects: 0
Study 15878725 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study 12117445 — intervention group
Group type: EXPERIMENTAL
Intervention: H-FABP
Number of subjects: 41
Study 12117445 — intervention group
Group type: COMPARATOR
Intervention: Myoglobin
Number of subjects: 41
Study 10344709 — intervention group
Group type: EXPERIMENTAL
Intervention: Survanta
Number of subjects: 89
Study 10344709 — intervention group
Group type: COMPARATOR
Intervention: Exosurf
Number of subjects: 89
Study 8568293 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms of vaccine
Number of subjects: 30
Study 8568293 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms of vaccine
Number of subjects: 30
Study 8568293 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 micrograms of vaccine
Number of subjects: 30
Study 8568293 — intervention group
Group type: COMPARATOR
Intervention: Alum adjuvant control
Number of subjects: 30
Study 1720370 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose bleomycin (60 units)
Number of subjects: 85
Study 1720370 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline (1 g)
Number of subjects: 85
Study 6812549 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (0.25 micrograms/kg/min)
Number of subjects: 25
Study 6812549 — intervention group
Group type: COMPARATOR
Intervention: Control (no nitroglycerin)
Number of subjects: 25
Study 31973701 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Health Clubs (CHCs) intervention
Number of subjects: 4056
Study 30601374 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidose metronidazole (500 mg twice daily for 7 days)
Number of subjects: 89
Study 30601374 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose metronidazole (2 g single-dose)
Number of subjects: 89
Study 29256535 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30mg daily
Number of subjects: 135
Study 29256535 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil 600mg daily
Number of subjects: 135
Study 29256535 — intervention group
Group type: COMPARATOR
Intervention: Healthy control
Number of subjects: 135
Study 26655100 — intervention group
Group type: EXPERIMENTAL
Intervention: Active balance exercises (progressive, highly challenging group exercise program, twice weekly for 90 minutes)
Number of subjects: 23
Study 26655100 — intervention group
Group type: EXPERIMENTAL
Intervention: Active balance exercises
Number of subjects: 23
Study 26655100 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 23
Study 25234605 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary treatment (D)
Number of subjects: 61
Study 25234605 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (DE)
Number of subjects: 61
Study 25234605 — intervention group
Group type: COMPARATOR
Intervention: Exercise (E)
Number of subjects: 61
Study 25234605 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 61
Study 21716151 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Water Immersion (CWI)
Number of subjects: 10
Study 21716151 — intervention group
Group type: COMPARATOR
Intervention: Passive Recovery (TPASS)
Number of subjects: 10
Study 18982438 — intervention group
Group type: EXPERIMENTAL
Intervention: Single vein (SV) approach
Number of subjects: 15
Study 18982438 — intervention group
Group type: COMPARATOR
Intervention: Double vein (DV) approach
Number of subjects: 15
Study 18021120 — intervention group
Group type: EXPERIMENTAL
Intervention: Explaining technical terms in consent forms
Number of subjects: 17
Study 18021120 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding of randomized controlled trials
Number of subjects: 17
Study 15214742 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral indomethacin
Number of subjects: 30
Study 15214742 — intervention group
Group type: COMPARATOR
Intervention: Intravenous indomethacin
Number of subjects: 30
Study 11210071 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioabsorbable barrier (polyglactin 910)
Number of subjects: 9
Study 11210071 — intervention group
Group type: COMPARATOR
Intervention: Non-resorbable barrier (expanded polytetrafluoroethylene [ePTFE])
Number of subjects: 9
Study 11210071 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (bioabsorbable and non-resorbable barriers)
Number of subjects: 9
Study 9738165 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 0
Study 9738165 — intervention group
Group type: COMPARATOR
Intervention: Stent implantation
Number of subjects: 0